Filmed at ASCO 2026, Rick Van Etten, MD, PhD, director of the UCI Health Chao Family Comprehensive Cancer Center, discusses one of the meeting’s most closely watched pancreatic cancer updates: results from the phase 3 RASolute 302 trial of hashtag#daraxonrasib.

For decades, KRAS has been recognized as a major cancer driver, including in pancreatic, lung, cervical and gastrointestinal cancers, but it was long considered “almost undruggable.”

UCI Health had the RASolute 302 trial open from the beginning, with Jennifer Valerin, MD, PhD, helping lead patient accrual at our cancer center.

For community physicians in Orange County and the surrounding region, this is also a reminder of the role an NCI-designated comprehensive cancer center can play: partnering to expand access to clinical trials, emerging therapies and new options for patients facing difficult-to-treat cancers.